Evaluation of serum glucose-regulated protein 78 (GRP78) as a biomarker of treatment response to bortezomib-based induction regimen in multiple myeloma: A cross-sectional pilot study.
Sign Up to like & getrecommendations! Published in 2022 at "Neoplasma"
DOI: 10.4149/neo_2022_220526n564
Abstract: GRP78 overexpression in myeloma cells has been associated with bortezomib resistance in multiple myeloma (MM). However, serum GRP78 as a maker of bortezomib-based treatment response remains unexplored. The objective of the study was to evaluate… read more here.
Keywords: based induction; grp78; serum grp78; bortezomib based ... See more keywords